Skip to content

Clinical trials

Observational Adenocarcinoma of Lung trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Adenocarcinoma of Lung Phase: Observational Clear all

90 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20041
20071
20084
20091
20102
20113
20124
20131
20146
20166
20172
20185
20198
20205
20216
202213
20237
20247
20252
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status33
Completed29
Recruiting16
Not yet recruiting6
Withdrawn2
Terminated2
Enrolling by invitation1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fudan University6
Alliance for Clinical Trials in Oncology5
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology5
Shanghai Pulmonary Hospital, Shanghai, China4
Central Hospital, Nancy, France3
ECOG-ACRIN Cancer Research Group3
Geneplus-Beijing Co. Ltd.3
Cancer Institute and Hospital, Chinese Academy of Medical Sciences2
China Medical University Hospital2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Adenocarcinoma of Lung90
Lung Neoplasms38
Carcinoma, Non-Small-Cell Lung29
Adenocarcinoma, Bronchiolo-Alveolar5
Pancreatic Neoplasms4
Lung Diseases3
Neoplasms3
Small Cell Lung Carcinoma3
Bronchial Neoplasms2
Cholangiocarcinoma2

Trials

Showing 76 to 90 of 90. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.